Creating new male contraceptives using small molecule inhibitors
Development of small molecule inhibitors of RBM46 as novel male contraceptives
This study is exploring new ways for men to prevent pregnancy by targeting a protein important for sperm production, aiming to create a safe and easy-to-use non-hormonal contraceptive that can be reversed when desired.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas San Antonio NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11016997 on NIH RePORTER |
What this research studies
This research focuses on developing innovative male contraceptive methods by targeting a specific protein called RBM46, which is crucial for sperm production. The approach involves creating small molecules that can inhibit this protein, potentially leading to a safe and effective way to prevent pregnancy in men. The research aims to provide a non-hormonal contraceptive option that is reversible and easy to use. By combining expertise in drug development and male reproductive health, the project seeks to advance new contraceptive solutions to clinical application.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would be adult males who are seeking contraceptive options.
Not a fit: Patients who are not male or those who do not wish to use male contraceptive methods may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide men with a reliable and reversible contraceptive option, helping to reduce unintended pregnancies.
How similar studies have performed: While the approach of targeting RBM46 is novel, previous research has shown promise in developing male contraceptives through similar mechanisms.
Where this research is happening
San Antonio, United States
- University of Texas San Antonio — San Antonio, United States (Active)
Researchers
- Principal investigator: Hermann, Brian Peter — University of Texas San Antonio
- Study coordinator: Hermann, Brian Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.